Abstract
A microbiological assay has been developed for chromomycin A3, an antitumor antibiotic showing promise in human trials. The assay bacterium is a derived strain of Streptococcus faecalis resistant to methotrexate. Studies with mice revealed that relatively high concentrations of this antibiotic were maintained in the blood, kidneys, and liver of mice after a single-dose intraperitoneal injection of the drug.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gause G. F. Olivomycin, mithramycin, chromomycin: three related cancerostatic antibiotics. Adv Chemother. 1965;2:179–195. doi: 10.1016/b978-1-4831-9930-6.50009-5. [DOI] [PubMed] [Google Scholar]
- KAZIWARA K., WATANABE J., KOMEDA T., USUI T. Further observations on the inhibiting effects of chromomycin A3 on transplantable tumors. Cancer Chemother Rep. 1961 Jul;13:99–106. [PubMed] [Google Scholar]
- KURU M. Clinical experience with a new antitumor agent chromomycin. Cancer Chemother Rep. 1961 Jul;13:91–97. [PubMed] [Google Scholar]
- Pittillo R. F., Hunt D. E. Cytosine arabinoside sensitivity in actinobolin-resistant Streptococcus faecalis: the basis of a utilitarian microbiological assay. Proc Soc Exp Biol Med. 1967 Feb;124(2):636–640. doi: 10.3181/00379727-124-31811. [DOI] [PubMed] [Google Scholar]